The "Human Brain Mapping Project" will substantially increase the value of the company's patented MANF technology.
Potential buyout target.
My best friend said to buy Amarantus Bioscience (AMBS) at seven cents. That it will be $1.00 by the end of the year. The company's patented MANF technology has the potential to treat a number of neurological diseases.
Amarantus Bioscience - AMBS.
The company's patented MANF technology could treat a myriad of neurological diseases including Parkinson's Disease. A "big pharma" partnership or buyout could move the share price over $1.00 this year.
Bonanza Goldfields - BONZ - First revenue report due out at any time. The company's Tarantula site in Arizona started production in December. One of the only gold mining operations in Arizona. Visit the company's website to view pictures/video of the site.
"Penny stock today. Dollar stock tomorrow."
Company's C.E.O. was a former director at the U.S. Mint.
A current value in the $100,000,000 range is quite reasonable.
Considering the potential impact of the "Human Brain Mapping Project", the investment to date of approximately $35,000,000 in developing the patented MANF technology, and the value attached to Amarantus Diagnostics, and the fact that the GDNF technology sold for $265,000,000 I would attach a current value to Amarantus Bioscience in the $100,000,000 range or about .45/share.
A joint venture or "big pharma" partnership announcement and the resulting short squeeze could take it much higher ($1.00?) but it would probably settle in the .45-.50 range.
In regards to valuation one might consider that at the time of the last F.D.A. decision on Afrezza that Mannkind's market cap was $1.22 billion. If Mannkind fails to find a partner before the next decision is there any reason to believe that Mannkind's market cap would be substantially higher at the time of the third ruling on Afrezza?
Using the 550,000,000 share figure from the Seeking Alpha article and the previous $1.22 billion market cap the expected share price at the time of the next ruling sans a marketing partner would put the share price in the $2.20 range.
Obviously a higher share price prior to the F.D.A.'s decision is substantially dependent on two things: 1. Exceptionally good trial results and 2. A "big pharma" marketing partner. Both of which would be subsequent to an eventual approval if it happens.
Interesting year ahead for the Mannkind shorts and shareholders.
Checkout Amarantus Bioscience - AMBS. It's patented MANF technology could hold the cure for a myriad of neurological diseases such as Parkinson's Disease and Alzheimer's Disease.
Substantially more upside in 2013 than Mannkind moving forward.
AMBS is currently at .078 and Mannkind is at $3.06. Would you like to place a little wager as to which stock performs better on a percentage basis between now and December 31,2013?
The loser donates the amount of the wager to the Salvation Army.
I don't expect you to take the bet. I know I wouldn't.
From Yesterday's Seeking Alpha Article:
Amarantus BioScience (AMBS.OB) is an interesting name whose story has been generating a buzz in 2013. The company's main product in development is MANF, a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of several apoptosis-related disorders. It is one of the four main protein therapies currently in testing for Parkinson's along with GDNF, Neurturin, and NGF. MANF's discovery protocols, utilizing their proprietary PhenoGuard Protein Discovery Engine, were designed to identify a molecule that would be highly selective for dopamine producing neurons of the Substantia Nigra.
Amarantus' chances with MANF just received a boost after Phytopharm, a UK company, failed in its attempt to develop a successful treatment for Parkinson's. Phytopharm's strategy for Parkinson's was a small molecule used in an attempt to reinvigorate the dead cells and raise the protein levels. To that effect, it obviously didn't succeed but it did narrow down the options available for Parkinson's. The other two methods currently in development to cure Parkinson's are gene and protein therapy, as mentioned above. Amarantus owns rights for both. A gene therapy for Parkinson's is currently in development by Ceregene, a private company, and results from the company's Phase 2b study for Parkinson's are expected in early 2013. Looking forward, that data should help provide some clarity in the gene versus protein therapy battle and serve as a catalyst for Amarantus shares once results come out and headlines start swirling.
The market size for Parkinson's disease is estimated to be $5 billion a year. Taking that fact into consideration in combination with MANF's potential in Parkinson's disease, makes the stock attractive. MANF and the other neurotrophic factors have several advantages over what is currently available on the market. They help regenerate cells, protect current cells, and prevent further worsening of the Parkinson's condition. The current treatments for Parkinson's just cover up the symptoms. In addition to the fact that you can only do that for so long before the underlying cells continue to fail, they also lead to side effects as it is nearly impossible to provide the right dosage required.
Amarantus is a micro-cap stock and many micro-cap stocks tend to be new and have no proven track record. Some of these companies have no assets or operations. Others have products and services that are still in development or have yet to be tested in the market.